Best Practices for the Multidisciplinary Care of Patients With Early-Stage Driver-Mutated Non-Small Cell Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Thoracic Surgery

Background:

• ALK-positive non-small cell lung cancer (NSCLC) is a distinct molecular subtype.
• Treatment paradigms are evolving due to targeted therapies and molecular testing.
• Recent trials like ALINA and ADAURA highlight advancements in ALK-positive NSCLC treatment.

Purpose of the Study:

• To summarize current treatment strategies for early-stage ALK-positive NSCLC.
• To highlight the impact of targeted therapies and molecular testing.
• To discuss emerging neoadjuvant treatment approaches.

Main Methods:

• Review of key clinical trials (ALINA, ADAURA, NAUTIKA1, NeoADAURA).
• Analysis of advances in molecular testing and targeted therapies.
• Emphasis on multidisciplinary care and surgical staging.

Main Results:

• Targeted therapies have significantly improved outcomes in ALK-positive NSCLC.
• Neoadjuvant targeted therapy is an emerging area of investigation.
• Multidisciplinary collaboration is crucial for optimal patient management.

Conclusions:

• Individualized, multidisciplinary care is essential for ALK-positive NSCLC.
• Continued research and clinical trial participation are vital.
• Advances in targeted therapy and neoadjuvant strategies offer improved survival.